Personalis to Participate in 25th Annual Needham Virtual Conference

Personalis to showcase advanced genomics for precision oncology at leading industry event.

Apr. 2, 2026 at 7:22am

Got story updates? Submit your updates here. ›

Personalis, Inc., a leader in advanced genomics for precision oncology, announced that its management team will be participating in the 25th Annual Needham Virtual Conference on Wednesday, April 15, 2026. The company aims to transform cancer management through personalized testing and insights that guide care throughout the patient journey.

Why it matters

Personalis is at the forefront of precision oncology, leveraging highly sensitive assays and proprietary algorithms to detect minimal residual disease, enable targeted therapy selection, and enhance biomarker strategy for drug development. Its participation in the prestigious Needham conference underscores the company's leadership in this rapidly evolving field.

The details

Personalis will showcase its advanced genomics capabilities and cancer management solutions at the 25th Annual Needham Virtual Conference. The company's products are designed to detect cancer recurrence early, guide targeted therapy selection, and support drug development through comprehensive genomic profiling and biomarker strategies.

  • The 25th Annual Needham Virtual Conference will take place on Wednesday, April 15, 2026.

The players

Personalis, Inc.

A leader in advanced genomics for precision oncology, transforming the active management of cancer through personalized testing and insights.

Caroline Corner

Investor Relations at Personalis, Inc.

Got photos? Submit your photos here. ›

What they’re saying

“Personalis is at the forefront of precision oncology, leveraging highly sensitive assays and proprietary algorithms to detect minimal residual disease, enable targeted therapy selection, and enhance biomarker strategy for drug development.”

— Caroline Corner, Investor Relations

The takeaway

Personalis' participation in the prestigious Needham conference highlights its leadership in the rapidly evolving field of precision oncology, where the company's advanced genomics solutions are transforming cancer management and guiding care throughout the patient journey.